Trial Profile
An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jan 2022
Price :
$35
*
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms PRO-MSACTIVE
- Sponsors Roche
- 10 Jan 2022 Status changed from active, no longer recruiting to completed.
- 22 Jun 2021 Interim results (n=335) of week 48 presented at the 7th Congress of the European Academy of Neurology
- 22 Jun 2021 Results (n=335; at 48-weeks treatment period) assessing efficacy and safety of ocrelizumab in patients with active relapsing multiple sclerosis, presented at the 7th Congress of the European Academy of Neurology.